“Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial” (2017) SKIN The Journal of Cutaneous Medicine, 1(3.1), p. s129. doi: 10.25251/skin.1.supp.128.